AtriCure, Inc. ATRC
56.46 USD -1.07 (-1.86%)
Nov 12, 2026, 2:59 PM EST
56.19 Day range 58.24
25.36 52-week range 66.02
- YTD
- +42.72%
- 1 year
- +70.78%
News
seekingalpha.com AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript AtriCure, Inc. ( ATRC ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Angela Wirick - Chief Financial Officer Conference Call Participants Patrick Andrew…
seekingalpha.com AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy AtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. Upcoming catalysts include the STS quality metric…
benzinga.com Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67 Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $67.
benzinga.com Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70 Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.
benzinga.com AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure beat Q3 estimates, raised FY2026 EPS and sales guidance, and saw analysts lift price targets to $70; shares fell 2%.
benzinga.com Needham Maintains Buy on AtriCure, Raises Price Target to $70 Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $70 BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.
benzinga.com AtriCure Q3 2026 Earnings Call Transcript AtriCure (NASDAQ:ATRC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com AtriCure Q3 Adj. EPS $0.17 Beats $(0.05) Estimate, Sales $154.450M Beat $151.217M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.05) by 440 percent. This is a 1800 percent increase over losses of $(0.01) per…
benzinga.com AtriCure Raises FY2026 Adj EPS Guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 Est; Raises FY2026 Sales Guidance from $602.000M-$610.000M to $606.000M-$610.000M vs $606.219M Est AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 analyst estimate. Raises FY2026 sales outlook from $602.000 million-$610.000 million to $606.000…- benzinga.com Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68 Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $63 BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.
benzinga.com Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
benzinga.com This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
benzinga.com Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57 Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.- benzinga.com Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com Salesforce To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor…- benzinga.com Needham Maintains Buy on AtriCure, Raises Price Target to $64 Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.
benzinga.com Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60 Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.
benzinga.com Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.- benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $55 BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $55.
benzinga.com Top 3 Health Care Stocks That May Implode This Month RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences- benzinga.com UBS Maintains Buy on AtriCure, Lowers Price Target to $50 UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $55 to $50.
benzinga.com AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you…- benzinga.com AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 1000 percent increase over losses of $(0.02)…
- benzinga.com AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026 Sales Guidance from $600.000M-$610.000M to $602.000M-$610.000M vs $604.990M Est AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analyst estimate. Raises FY2026 sales outlook from $600.000 million-$610.000 million to $602.000…
benzinga.com Earnings Scheduled For July 23, 2026 Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…
benzinga.com Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55 Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.
benzinga.com AtriCure Q1 2026 Earnings Call Transcript - benzinga.com AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est 2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610 million, and management also projects full year 2026 Adjusted EBITDA of approximately $80 million…
- benzinga.com Earnings Scheduled For May 5, 2026
benzinga.com This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com Earnings Scheduled For October 29, 2025 
benzinga.com Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Earnings Scheduled For July 29, 2025
- benzinga.com Earnings Scheduled For April 29, 2025
- benzinga.com Earnings Scheduled For February 12, 2025
- benzinga.com Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
- benzinga.com Earnings Scheduled For February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 1, 2023 Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
- benzinga.com Earnings Scheduled For July 25, 2023 Companies Reporting Before The Bell • Unilever (NYSE:UL) is expected to report earnings for its first quarter. • Lilium (NASDAQ:LILM) is estimated to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For February 21, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is likely to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 1, 2022 Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
- benzinga.com Earnings Scheduled For August 2, 2022 Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.